Q2 Earnings Forecast for RVPH Issued By Zacks Research

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Research analysts at Zacks Research issued their Q2 2026 earnings estimates for shares of Reviva Pharmaceuticals in a report released on Wednesday, May 27th. Zacks Research analyst J. Vandermosten anticipates that the company will post earnings per share of ($0.36) for the quarter. The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($2.96) per share. Zacks Research also issued estimates for Reviva Pharmaceuticals’ Q3 2026 earnings at ($0.55) EPS, Q4 2026 earnings at ($0.55) EPS and FY2028 earnings at ($0.51) EPS.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its earnings results on Thursday, May 14th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.10).

Several other equities analysts have also commented on the stock. Wall Street Zen raised shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, April 11th. D. Boral Capital lowered shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, March 5th. Maxim Group lowered shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, April 8th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a report on Tuesday, April 21st. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Reviva Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $66.67.

Reviva Pharmaceuticals Stock Down 4.3%

RVPH stock opened at $0.38 on Thursday. Reviva Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $23.00. The firm has a market cap of $5.02 million, a P/E ratio of -0.09 and a beta of 0.75. The company’s 50-day moving average price is $0.78 and its two-hundred day moving average price is $5.24.

Institutional Investors Weigh In On Reviva Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Armistice Capital LLC acquired a new stake in Reviva Pharmaceuticals during the 2nd quarter worth approximately $1,026,000. Millennium Management LLC boosted its position in Reviva Pharmaceuticals by 15.0% during the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock worth $631,000 after buying an additional 223,178 shares during the period. Geode Capital Management LLC boosted its position in Reviva Pharmaceuticals by 87.6% during the 4th quarter. Geode Capital Management LLC now owns 1,048,954 shares of the company’s stock worth $293,000 after buying an additional 489,711 shares during the period. State Street Corp boosted its position in Reviva Pharmaceuticals by 202.4% during the 4th quarter. State Street Corp now owns 383,200 shares of the company’s stock worth $107,000 after buying an additional 256,500 shares during the period. Finally, XTX Topco Ltd boosted its position in Reviva Pharmaceuticals by 63.6% during the 4th quarter. XTX Topco Ltd now owns 164,291 shares of the company’s stock worth $46,000 after buying an additional 63,893 shares during the period. 63.18% of the stock is currently owned by institutional investors and hedge funds.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.